

GPTHEALTH/CS/SE/2025-26

November 8, 2025

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
ISIN: INE486R01017	

Dear Sir/Madam

Sub: Submission of Investor Presentation on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2025:

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a copy of Investor Presentation on Audited Financial Results (Standalone) for the Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2025 for dissemination to general public and Investors.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

For GPT Healthcare Limited

ANKUR
SHARMA
Digitally signed
by ANKUR
SHARMA
Date: 2025.11.08
16:45:46 +05'30'

Ankur Sharma
Company Secretary and Compliance Officer
M. No A31833

Encl. As Above.



GPT Healthcare Limited

Investor Presentation – H1 FY26

NSE: GPTHEALTH | BSE: 544131

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **GPT Healthcare Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contractor binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

"कर्मण्येवाधिकारस्ते मा फलेषु कदाचन।
मा कर्मफलहेतुर्भूर्मा ते संगोऽस्त्वकर्मणि॥



Karmyogi and Samaj Sevak

Late Shri Dwarika Prasad Tania

May 27, 1954 - August 17, 2025

He was our North Star, a true karmyogi whose life was a testament to purpose and perseverance.

He showed us that greatness lies in humility and that integrity is the finest legacy.

A true leader who always believed in strong family bonding and teamwork.

Through his vision and actions, he left our world richer, wiser, and better than he found it.

Farewell to our mentor, our inspiration. His light will guide us forever.

May his noble soul find eternal peace at the Lotus feet of Lord Narayan.

1



H1 FY26
Performance

2



Company
Overview

3




Business
Highlights

4



Annual
Financials







Q2 & H1 FY26 Performance


- ✓ Strategically located in **Densely Populated Micro Markets** of Kolkata, Howrah, Agartala and Raipur
- ✓ Established **Right-Sized, Full-Service Hospitals** according to each sub-region, aids **High Return on Capital**
- ✓ The company has declared a dividend of Re 1 per share









 Capabilities Built so far	719 Beds - Total capacity	112 Full-time consultants	620 Visiting consultants	5 Full service Multispecialty Hospitals	NABH & NABL accreditations
 Five Multispecialty Hospitals	ILS Salt Lake	ILS Agartala	ILS Dum Dum	ILS Howrah	ILS Raipur
 Robust Financials (H1 FY26)	Rs 228.92 Cr Total Income	18.79% EBITDA Margin	44.7% Bed Occupancy	~Rs 38,376 ARPOB 3.49 days ALOS	11.7% *ROCE H1 FY26 7.4% *ROE H1 FY26

* Not annualized





Hospital wise Performance – H1FY26

	Year of Commissioning	Bed Capacity (No. of Beds)	Revenue (Rs in Crore)	Bed Occupancy Rate (%)	ARPOB (Rs Per day)
Salt Lake Hospital	2000	85	39.3	 61.56%	41,062
Agartala Hospital	2011	205	69.2	 52.72%	34,993
Dum Dum Hospital	2013	155	76.5	 64.15%	42,033
Howrah Hospital	2019	116	30.8	 41.62%	34,822
Raipur Hospital	2025	158	9.9	 10.11%	40,869
Total		719	225.7	 44.70%	38,376

Profit & Loss Highlights – Q2 & H1 FY26

Particulars (Rs Cr)	Q2FY26	Q2FY25	YoY	Q1 FY26	QoQ	H1FY26	H1FY25	YoY
Revenue from operations	118.9	105.7	12.5%	107.1	11.0%	226.0	203.5	11.1%
Other Income	1.3	2.8	-52.3%	1.6	-14.4%	2.9	5.0	-42.4%
Total Income	120.2	108.5	10.9%	108.7	10.7%	228.9	208.5	9.8%
Cost of materials consumed	22.2	20.3	9.2%	20.7	7.3%	42.9	38.7	10.9%
Employee benefits expense	20.3	17.7	14.5%	20.4	-0.6%	40.7	36.5	11.7%
Other expenses	53.7	44.2	21.5%	48.7	10.3%	102.3	87.0	17.7%
EBITDA	24.1	26.3	-8.2%	18.9	27.2%	43.0	46.4	-7.4%
<i>EBITDA Margin</i>	<i>20.0%</i>	<i>24.2%</i>	<i>-420bps</i>	<i>17.4%</i>	<i>260 bps</i>	<i>18.8%</i>	<i>22.2%</i>	<i>-340bps</i>
Depreciation and amortization expenses	6.8	4.8	42.6%	6.2	10.8%	13.0	9.5	37.4%
Finance Costs	2.2	0.7	192.3%	1.6	32.5%	3.8	1.6	137.2%
Profit before tax	15.1	20.7	-27.2%	11.1	31.6%	26.2	35.3	-25.9%
Tax expense	4.5	5.9	-26.2%	3.4	29.8%	7.9	10.6	-25.4%
PAT	10.6	14.8	-24.1%	7.7	38.2%	18.3	24.7	-26.2%
<i>PAT Margin</i>	<i>8.8%</i>	<i>13.7%</i>	<i>-490bps</i>	<i>7.1%</i>	<i>170 bps</i>	<i>8.0%</i>	<i>11.9%</i>	<i>-390 bps</i>
EPS (Rs per Share)	1.25	1.8		0.9		2.2	3.0	



Existing Hospitals

- ✓ New offering at Howrah Hospital: Commenced Robotic Knee Surgeries which will further enhance the ARPOB and reduce the ALOS.
- ✓ **New offering at Agartala Hospital:** Comprehensive Cancer Care Department including PET scan and LA in Radiation Oncology, making it the only unit of its kind in Tripura.
- ✓ **Ramp up Occupancy at Agartala and Howrah Hospitals:** Plans to ramp up the current occupancy rate of ~55% to optimum rate of 70-75%.



New Hospital

- ✓ Setting up hospitals on Asset-light basis where investment in land and building construction would be borne by the owner and the developer of the land in return for periodic rent payments:

Jamshedpur, Jharkhand – 150 Beds; Estimated cost of Rs 75 Cr and Commissioning is expected by the end of FY27

- ✓ Plan to expand operations to other Tier II cities of near states such as Uttar Pradesh, Assam, and Odisha and also strategic locations in Tier I cities of Eastern India



Continued Investment in Infrastructure

- ✓ Installed cutting-edge robotic surgical technology in Salt Lake and Howrah Hospital with 700+ robotic surgeries successfully performed from the robot in Salt Lake.
- ✓ Set up a 3D imaging to enable interventional neurology cases at Dum Dum Hospital

ILS-MyHealth: Healthcare mobile app, to allow patients seamlessly book appointments and access medical information on a real time basis

Installed HMIS: Software to create an internal digitalized system for maintaining electronic medical records



Company Overview



Total 85 Beds, a high end Surgical centre with Robot enabled Operating theatre



The Department of Minimal Access Surgery is **accredited by National Board of Examinations** for training of post-graduate surgeons under the Fellowship of National Board in Minimal Access Surgery




Awarded the title of '**Center of Excellence in Metabolic and Bariatric Surgery**', by Surgical Review Corporation, USA & Received the '**Ananda Swasthya Samman 2022**' from Ananda Bazar Patrika for excellence in customer care and support




Conducted 700+ successful Robotic surgeries



Bed Occupancy Rate



ARPOB (Rs per day)





Total 205 Beds, including 66 Beds across ICUs along with 8 OTs & 1 catheterization laboratory



The **only NABH accredited** hospital in Agartala and **one among 11 valid accredited hospitals** in North-East India as of October 2023. Also **accredited by NABL**




Received the '**Excellence in Community Engagement Award**' in 2021 from the Association of Healthcare Providers




Conducted "**Lead less dual chamber implantation**" which is done 1st time in Tripura and 6th in India.
Conducted "**Sub-Clavian and vertebral artery stenting**" which is done 1st time in Tripura
Started to do Radiation Oncology, done over 700 procedure in 4 months



Bed Occupancy Rate



ARPOB (Rs per day)





Total 155 Beds, including 53 Beds across ICUs and HDUs along with 4 OTs & 1 catheterization laboratory



NABH accredited and **NABL accredited** for complying with ISO 15189:2012 standards in the field of medical testing




Recognized by the CII for Excellence in Nursing for their efforts, commitment and contribution during the COVID-19 pandemic




Licensed to perform renal transplants and performed 65 such surgeries in H1 FY26
Shortly commencing Cardiac Surgery



Bed Occupancy Rate



ARPOB (Rs per day)





Total 116 Beds, including 43 Beds across ICUs and HDUs along with 3 OTs & 1 catheterization laboratory



Near Howrah station, the site holds strong potential with no hospital within 5 km




Recognized by the CII for Excellence in Nursing for their efforts, commitment and contribution during the COVID-19 pandemic




Commenced robotic knee replacement surgeries and performed 34 such surgeries till H1 FY26.



Bed Occupancy Rate



ARPOB (Rs per day)



New ILS Raipur Hospital – (May 2025)



Quaternary Care, 158 beds including ICUs & HDUs, 5 OTs, and Oncology facilities.



At Pachpedi Naka, Raipur, the facility will serve patients across Raipur, Bilaspur, Durg, and Bhilai.



Equipped with 3 Tesla MRI, Cardiac Cath Lab and Dual Source CT Scan for precise diagnostics.



Highly skilled clinicians and trained staff ensuring top-quality patient care



Started Renal transplants, Chemotherapy and Oncology Surgeries, received license for liver transplant

10%

Bed Occupancy

~Rs 40,869

ARPOB



Specialties

Medicine	Cardiac Sciences	Critical Care	Diabetics
Gynecology & Obstetrics	Reproductive Medicine	Medical & Surgical Oncology	Neonatal and Pediatrics
General & Specialty Surgeries	Laparoscopic Surgeries	Gastroenterology	Orthopedics
Neuro Sciences	Nephrology	Urology & Acute Kidney Dialysis	ENT






Business Highlights



Strategic Location of the Hospitals

Being in populous neighbourhoods builds familiarity with the local population and enables accessibility to our hospitals



Right Sized, Full Service

Operating multispecialty, mid sized hospitals with:

Number of beds ranging from 85 to 205

Affordable ARPOB at Rs 38,376



Disciplined Approach towards Costs

Strategic measures towards capital / cost optimization such as long-term lease model for some of the hospitals and other initiatives led to:

Capex per bed at ~Rs 7 to 8 Mn, lower than industry standards, leading to higher ROCE

EBITDA breakeven in short time spans


- Dum Dum hospital in 10 months
- Howrah hospital in 8 months



Brand Strength demonstrated through Payor Mix

Very low dependence on business from Corporates and Government Schemes

Payor Mix (H1 FY26)



Cash to EBITDA at 89% as at FY25

Professional and experienced leadership – Board of Directors



Dr. Om Tania
Chairman & Managing Director



- Founding member of ILS Hospitals
- More than 40+ years of experience as a medical practitioner
- Recognised as a surgeon of excellence by Surgical Review Corporation, USA
- Fellow Member of the Association of Surgeons of India in general surgery
- Served as President of Association of the Minimal Access Surgeons of India



Shree Gopal Tania
Vice Chairman

- More than 40 years of experience in administrative and corporate governance roles



Anurag Tania
Executive Director



- 12+ years of experience in healthcare management and looks after the daytoday operations of the Company
- Holds Bachelor of Science in Management with honours from University of Illinois



Dr. Aruna Tania
Non - Executive Director



- Senior consultant (gynaecology and obstetrics) in ILS Hospitals
- 36+ years of experience as a medical practitioner
- Holds Bachelor of Medicine and Bachelor of Surgery from Ravindra Nath Tagore Medical College, Udaipur, University of Rajasthan and Master of Surgery in Obstetrics and Gynaecology from Bhupendra Narayan Mandal University, Bihar
- Fellow of The Association of Minimal Access Surgeons of India- FMAS



Dr. Ghanshyam Goyal
Non - Executive Director

- HOD of Diabetology at Salt Lake hospital since the year 2000
- Experience in general medicine and diabetology
- Holds Bachelor of Medicine, Bachelor of Surgery and Doctor of Medicine in general medicine from S.M.S. Medical College, University of Rajasthan



Kashi Prasad Khandelwal
Non-Executive Independent Director



- More than 4 decades of experience as a Chartered Accountant & expertise in Audit, Accounting, Direct and Indirect Tax, Corporate law matters.



Dr. Tapti Sen
Independent Director



- Experience of almost 35 years as a medical practitioner
- Bachelor of Medicine, Bachelor of Surgery and Master of Surgery from University of Nagpur
- Serves as the Secretary of Kolkata Breast Health and Welfare Association



Hari Modi
Independent Director



- Graduated from the University of Calcutta and has passed the final examination of the Institute of Cost and Works Accountant of India



Deepak Pramanik
Independent Director



- 30+ years of experience in management consultancy, human resources and finance
- Bachelor degree in Technology in Mechanical Engineering from IIT, Madras and a Post Graduate Diploma in Management from IIM, Calcutta



Amrendra Prasad Verma
Independent Director



- Experience in credit, finance and banking sectors
- Served as the MD and CEO of SBI Capital Markets Ltd and as a Deputy MD and Group Executive (Mid Corporate) and Chief Credit and Risk Officer of the State Bank of India



Member



Chairman



Stakeholders Relationship Committee



CSR Committee



Executive Committee



Audit Committee




Nomination & Remuneration Committee




Annual Performance

Key Financial Metrics


Revenue from Operations (Rs Cr)




EBITDA & EBITDA Margin




PAT & PAT Margin








ROE (%) and ROCE (%)



Net Debt to Equity (X times)





Diverse Revenue Mix Across Top 10 Specialties

- Internal Medicine & Diabetology

■ Paediatrics

■ Orthopaedics and Joint Replacement
- Nephrology


■ Gastroenterology

■ Neurosciences
- General Surgery


■ Gynaecology and obstetrics

■ Others
- Critical Care


■ Interventional cardiology



FY 24



FY 25



H1 FY26

Balance Sheet


Assets (Rs Cr)	Mar-25	Sep-24	Sep-25
PPE	202.6	198.7	261.6
Other Non-Current Asset	46.3	55.4	114.5
Investments	56.5	22.9	-
Non-Current Assets	305.4	277.0	376.1
Inventories	8.9	9.1	12.3
Debtors	19.7	28.2	28.1
Cash Eq. and Bank	4.3	4.5	1.9
Loans	0.2	0.8	1.2
Investments	31.9	16	31.7
Other Current Assets	13.8	11.2	12.2
Current Assets	78.8	69.8	87.4
Total Assets	384.2	346.8	463.5

Liabilities (Rs Cr)	Mar-25	Sep-24	Sep-25
Share Capital	82.1	82.1	82.0
Other Equity	165.8	148.9	171.8
Total Equity	247.9	231	253.8
Borrowings	5.5	2.3	10.2
Lease Liabilities	17.2	15.4	71.0
Other Non-Current Liabilities	39.5	34.4	43.8
Non-Current Liabilities	62.2	52.1	125.0
Borrowings	7.8	6.8	10.1
Trade Payables	34.7	36.8	48.7
Provisions	0.6	2.2	0.6
Other Financial Liabilities	20.2	9.3	14.4
Other Current Liabilities	10.9	8.6	10.9
Current Liabilities	74.2	63.7	84.7
Total Liabilities	384.3	346.8	463.5


Particulars (Rs Cr)	FY25	H1FY25	H1FY26
Revenue from operations	407.1	203.5	226.0
Other Income	8.5	5.0	2.9
Total Income	415.6	208.5	228.9
Cost of materials consumed	78.8	38.7	42.9
Employee benefits expense	73	36.5	40.7
Other expenses	171.9	87.0	102.3
EBITDA	91.9	46.4	43.0
<i>EBITDA Margin</i>	<i>22.1%</i>	<i>22.2%</i>	<i>18.8%</i>
Depreciation and amortisation expenses	19.0	9.5	13.0
Finance costs	3.5	1.6	3.80
Profit before tax	69.4	35.3	26.2
Tax expense	19.4	10.6	7.9
PAT	50.0	24.7	18.3
<i>PAT Margin</i>	<i>12.0%</i>	<i>11.9%</i>	<i>8%</i>
EPS (Rs per Share)	6.1	3.0	2.19

Cash Flow Statement

Particulars (in Cr)	Mar-25	Sep-24	Sep-25
Cash Flow from Operating Activities			
Profit before Tax	69.3	35.4	26.2
Adjustment from Non-Operating Items			
Operating Profit before Working Capital	88.1	44.1	40.7
(Increase)/decrease in Inventories	-0.7	-0.9	-3.4
(Increase)/decrease in Trade Receivables	0.6	-5.8	-8.8
(Increase)/decrease in Payables & other Adjustments	-24.3	21.4	13.0
Cash generated from Operations	84.5	29.4	41.4
Less: Direct Taxes Paid	-17.1	-4.7	-7.8
Net Cash from Operating Activities	67.4	24.7	33.6
Net Cash flow from Investing Activities	-32.6	-4.5	-22.8
Net Cash flow from Financing Activities	-34.8	-18.7	-11.1
Net increase/(decrease) in Cash & Cash Equivalent	-0.03	1.6	-0.2
Add: Cash and Cash Equivalents as at 1st April	1.7	1.7	1.7
Cash and Cash Equivalents as at the end of period	1.7	3.3	1.5



Stock Price Chart as on 31-October-2025



Script Related Information (as on 31-October-2025)	
BSE/NSE Code	544131 GPTHEALTH
CMP (Rs)	148.55
Market Cap (Rs Cr)	1,219.60
Shares O/s (Cr)	8.21
Face Value (Rs)	10
Average Trading Volume ('000)	1,470

Thank You



GPT Healthcare Limited

CIN No.: L70101WB1989PLC047402

ir@gptgroup.co.in
+91-8981441481

For more details : www.ilshospitals.com